Company intelligence / Profile preview

VetoPhage

Lyon (Saint-Priest), Francevetophage.fr ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

VetoPhage has developed rapid detection tools for pathogenic bacteria responsible for bovine mastitis, which became available for the market in 2023. The company continues to develop phage cocktails as therapeutic solutions.

Therapeutic areas: Infectious Diseases
Modalities: BacteriophagesPhage-derived proteins (endolysins)
Industry: Veterinary

Drug pipeline

1 asset

LabMastis S.A

Commercial

Indications: Staphylococcus aureus detection in dairy farms

Partnerships

PHAXIAM Therapeutics (strategic research partnership announced October 3, 2023)

Beyond the preview

Go deeper on VetoPhage.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VetoPhage.

Explore the full profile